Skip to main navigation

Jump to navigation

Home
  • About
    • Mission and Values
    • Leadership Team
    • Board of Directors
    • Medical Advisors
  • Focus
    • Hyperoxaluria
    • Hyperuricemia
    • Publications
  • Products
    • ALLN-177
    • ALLN-346
    • Pipeline
    • FAQs
  • Investors
    • Overview
    • News Releases
    • In the News
    • Events and Presentations
    • Stock Information
    • Analyst Coverage
    • Corporate Governance
    • SEC Filings
    • Shareholder Services
  • Careers
  • Contact
  1. Home ›
  2. Investors

News Releases

News Releases

  • All News
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All News
  • 25
  • 50
  • November 10, 2014

    Summary ToggleAllena Pharmaceuticals To Present Data on Lead Program ALLN-177 at ASN Kidney Week 2014

    • Read more
  • April 29, 2014

    Summary ToggleAllena Pharmaceuticals Announces Positive Phase 1 Data of ALLN-177 for the Treatment of Kidney Stones

    • Read more
  • January 13, 2014

    Summary ToggleAllena Pharmaceuticals to Present at the 2014 J.P. Morgan Healthcare Conference

    • Read more
  • March 28, 2012

    Summary ToggleAllena Pharmaceuticals Licenses Worldwide Rights to Hyperoxaluria Portfolio from Althea Technologies

    • Read more
  • February 14, 2012

    Summary ToggleAllena Pharmaceuticals Appoints Gino Santini to Board of Directors

    • Read more
  • November 16, 2011

    Summary ToggleAllena Pharmaceuticals Launches with $15 Million Series A Round

    • Read more

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
Displaying 61 - 66 of 66 results

Investor Relations

  • Overview
  • News Releases
  • In the News
  • Events and Presentations
  • Stock Information
  • Analyst Coverage
  • Corporate Governance
  • SEC Filings
  • Shareholder Services
  • LinkedIn
  • LinkedIn
  • Privacy Policy
  • Terms of Use
  • Social Media Community Guidelines

©2019 Allena Pharmaceuticals, Inc. All rights reserved.